All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).
5 findings from 1 review
OR 0.69 [0.37, 1.26]
7 studies · 5935 participants
Low
OR 1.01 [0.06, 16.24]
5 studies · 1510 participants
Very low
OR 7 [0.14, 353.37]
1 study · 722 participants
Very low
Show 2 more findings
All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children with chronic asthma
Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).
1 finding from 1 review